Search

Displaying results 4561 - 4570 of 9333 in total
  1. Drug

    WNY0824

    go.drugbank.com/drugs/DB23606
    Experimental

    [A274253] It is a dual inhibitor of PLK-1 and BRET-4, which have both been found to be involved in CRPC via suppression of AR/MYC-mediated transcription. [A274258] … WNY0824 is a preclinical small molecule drug being investigated for the treatment of Castration-Resistant Prostrate Cancer (CRPC).

  2. Drug

    LY-517717

    go.drugbank.com/drugs/DB05713
    Investigational

    It is believed to be Lilly's PMD-3112 (licensed from Amgen).

  3. Drug

    CIGB 2020 Vaccine

    go.drugbank.com/drugs/DB15808
    Experimental

    The vaccine was developed and tested by the Center for Genetic Engineering and Biotechnology (CIGB), in Havana Cuba. … CIGB 2020 is a vaccine candidate administered nasally and sublingually, working to strengthen immunity in the areas administered.

  4. Drug

    (1H-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid

    go.drugbank.com/drugs/DB03455
    Experimental

    This compound belongs to the indole-3-acetic acid derivatives. … These are compounds containing an acetic acid (or a derivative) linked to the C3 carbon atom of an indole. (1H-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid is known to target interleukin-2.

  5. Drug

    Lepzacitinib

    go.drugbank.com/drugs/DB21646
    Investigational

    The usage of the INN stem '-citinib' in the name indicates that Lepzacitinib is a Janus kinase inhibitor. … Lepzacitinib is under investigation in clinical trial NCT05432596 (Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis).

  6. Drug

    4-Hydroxytestosterone

    go.drugbank.com/drugs/DB01485
    IllicitInvestigational

    It is specifically the 17-hydroxylated analog to formestane. … 4-Hydroxytestosterone is testosterone substituted with a hydroxy group on the fourth carbon atom.

  7. Drug

    ARCoV

    go.drugbank.com/drugs/DB15855
    Experimental

    It is the first COVID-19 mRNA vaccine to be approved for clinical trials in China, and was co-developed by Abogen Biosciences, Walvax Biotechnolgoy Co., Ltd. and the People’s Liberation Army (PLA) Academy … As of July 2020, the vaccine candidate is set for Phase 1 clinical trials to investigate for safety, tolerance, and immunogenicity (ChiCTR2000034112).

  8. Drug

    Neuropeptide Y

    go.drugbank.com/drugs/DB11788
    ApprovedInvestigationalWithdrawn

    Neuropeptide Y is under investigation for the basic science of Type 2 Diabetes Mellitus.

  9. Drug

    Carlumab

    go.drugbank.com/drugs/DB12718
    ApprovedWithdrawn

    Carlumab has been used in trials studying the treatment of Cancer and Prostate Cancer.

  10. Drug

    NNZ-2591

    go.drugbank.com/drugs/DB15601
    Investigational

    It was granted Orphan Drug Designation by the FDA in October 2019[L11103] and was granted a patent by the European Patent Office in December 2019. … [L11100] Clinical trials are expected to begin in 2020.[L11103,L11100]